Royalty Pharma (RPRX) EBT Margin (2019 - 2026)
Royalty Pharma (RPRX) reported EBT Margin of 74.26% for Q1 2026, down 219.0% on a YoY basis from 62.4% in Q1 2025, and up 29.77% sequentially from 57.22% in Q4 2025.
Royalty Pharma (RPRX) EBT Margin (2019 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 8 years of EBT Margin data on file, last reported at 74.26% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 219.0% year-over-year to 74.26%; the trailing twelve-month figure through Mar 2026 stood at 55.69% (down 2248.0% YoY), and the FY2025 full-year result was 55.68%, down 311.0% from the prior year.
- EBT Margin grew to 74.26% in Q1 2026, from 57.22% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 142.8% in Q3 2024 to a low of 107.83% in Q4 2022.
- A 5-year average of 50.53% and a median of 57.22% in 2025 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 11715 bps in 2022 and surged 22821 bps in 2023, its largest moves.
- Tracing RPRX's EBT Margin over 5 years: stood at 107.83% in 2022, then soared by 212 bps to 120.39% in 2023, then plunged by 53 bps to 56.32% in 2024, then advanced by 2 bps to 57.22% in 2025, then grew by 30 bps to 74.26% in 2026.
- Business Quant data shows RPRX's EBT Margin at 74.26% in Q1 2026, 57.22% in Q4 2025, and 72.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 74.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.26% |
| Dec 31, 2025 | 57.22% |
| Sep 30, 2025 | 72.91% |
| Jun 30, 2025 | 15.66% |
| Mar 31, 2025 | 76.45% |
| Dec 31, 2024 | 56.32% |
| Sep 30, 2024 | 142.80% |
| Jun 30, 2024 | 36.18% |
| Mar 31, 2024 | -0.75% |
| Dec 31, 2023 | 120.39% |
| Sep 30, 2023 | 22.76% |
| Jun 30, 2023 | 65.28% |
| Mar 31, 2023 | 74.43% |
| Dec 31, 2022 | -107.83% |
| Sep 30, 2022 | 38.44% |
| Jun 30, 2022 | 91.72% |
| Mar 31, 2022 | 22.79% |
| Dec 31, 2021 | 9.32% |
| Sep 30, 2021 | 37.86% |
| Jun 30, 2021 | 145.37% |